GBA Presents: THE GREEN MARKET

Well Van I'm moving big money tomorrow. $30,000+ trade. The stock you know.

I'm going to be ABBV Boy. Selling some country fund I didn't know I had and using some cash I raised buying 200 shares for myself and 200 for my wife.

My feeling - when you're on a hot streak keep pushing it.
 
These guys again-

WISeKey to invest $10M adapting cybersecurity tech to fend-off 'crypto jacking' » 16:14 WKEY


Global Payments initiated with a Buy at Loop Capital 16:07 GPN
 
stonedinvestor said:
Well Van I'm moving big money tomorrow. $30,000+ trade. The stock you know.

I'm going to be ABBV Boy. Selling some country fund I didn't know I had and using some cash I raised buying 200 shares for myself and 200 for my wife.

My feeling - when you're on a hot streak keep pushing it.
More...
Hmmmm.
That's almost as good as a Stoney "guarantee".

I'll look.

stonedinvestor said:
GET IN VAN I GAVE YOU A GUARANTEE REMEMBER
More...
This one QUOT is up a solid 7%.
:thumbsup:

ABBV certainly has a blowout chart, that's for sure.
Good call Stoney.
It's a tad bit pricey on a F/A level, but as long as nothing changes, it's a good stock.
If we get a nice pull-back, it'll be a great stock.

*** I am usually weary of stocks with dividends in excess of 4% though. Either something is up, or water seeks its level and you're a genius.
 

<< Stocks To watch >>

Nano Dimension sells DragonFly IV 3D-AME System to Western Defense Force 08:45 NNDM

Ooooooo. :caution:

Spero Therapeutics announces lifting of FDA clinical trial hold on SPR720 08:28 SPRO

Craig-Hallum bullish on iSpecimen, initiates with a Buy 08:25 ISPC As previously reported, Craig-Hallum analyst Matthew Hewitt initiated coverage of iSpecimen with a Buy rating and $20 price target. "Much the way Amazon has become the go-to platform for buyers and sellers of consumer goods," the analyst believes iSpecimen can become the go-to platform for human biospecimens. While the company was founded in 2009, it has only recently reached a critical mass of buyers and sellers, with revenue for 2021 on track to be nearly triple the 2019 level, Hewitt notes.

Draganfly announces it will be featured at EDGE22 08:24 DPRO

This better not be market moving!
AbbVie says FDA grants Breakthrough Therapy Designation to Teliso-V 08:17 ABBV AbbVie announced that the U.S. FDA granted Breakthrough Therapy Designation to investigational telisotuzumab vedotin for the treatment of patients with advanced/metastatic epidermal growth factor receptor wild type, nonsquamous non-small cell lung cancer with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy. The FDA's BTD program is intended to expedite the development and review of medicines with preliminary clinical evidence that indicate that the investigational treatment may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.
 
You must log in or register to reply here.
Back
Top